The remibrutinib MS treatment developed by Novartis has produced positive Phase III results in two pivotal studies involving adults with relapsing multiple sclerosis. The REMODEL-1 and REMODEL-2 trials both met their primary endpoint, with remibrutinib significantly reducing annualized relapse rates compared with teriflunomide. The investigational oral Bruton’s tyrosine kinase inhibitor also demonstrated advantages across key MRI measures and encouraging results related to disability progression.
The findings give Novartis additional evidence supporting remibrutinib as a potential oral treatment option for people who need strong disease control without some of the safety concerns associated with other BTK inhibitors.
Remibrutinib MS Treatment Reduces Relapses
The Phase III REMODEL programme compared remibrutinib with teriflunomide, an established oral therapy for relapsing multiple sclerosis.
The primary endpoint in both trials was annualized relapse rate, or ARR, which measures the average number of confirmed multiple sclerosis relapses experienced by a patient over one year.
Novartis reported that remibrutinib demonstrated statistically significant superiority over teriflunomide on this endpoint in both REMODEL-1 and REMODEL-2.
The result is important because relapses can cause new neurological symptoms or worsen existing ones. Preventing relapses remains a central objective of disease-modifying treatment in relapsing multiple sclerosis.
Remibrutinib MS Treatment Improves MRI Outcomes
Remibrutinib also performed better than teriflunomide across key secondary endpoints within each study, including measures of inflammatory brain lesions detected through magnetic resonance imaging.
MRI activity is an important measure in multiple sclerosis trials because new or enlarging lesions can provide evidence of ongoing inflammatory disease even when a patient is not experiencing an obvious clinical relapse.
The ability to reduce both clinical relapses and MRI-detected inflammatory activity strengthens the overall efficacy signal from the REMODEL programme.
Detailed numerical results have not yet been publicly presented. Novartis plans to disclose the full late-breaking dataset at MSToronto2026.
Disability Progression Shows Encouraging Signal
Preventing relapses is only part of effective multiple sclerosis management. Another major goal is delaying the accumulation of neurological disability.
Novartis said a preplanned pooled analysis of REMODEL-1 and REMODEL-2 showed clinically meaningful effects on disability progression.
The analysis demonstrated a positive trend in three-month confirmed disability progression and a nominally statistically significant effect on six-month confirmed disability progression.
These measures evaluate whether worsening on the Expanded Disability Status Scale persists for a defined period rather than reflecting a temporary change.
Remibrutinib MS Treatment Targets Disease Biology
Remibrutinib is a highly selective oral inhibitor of Bruton’s tyrosine kinase, or BTK.
BTK plays an important role in immune cells, including B cells and myeloid cells involved in inflammatory processes. Targeting the pathway could potentially influence immune activity associated with multiple sclerosis while providing an oral treatment option.
The REMODEL trials were randomized, double-blind and active-comparator controlled. ClinicalTrials.gov lists REMODEL-2 as enrolling approximately 800 participants and following patients for up to 30 months during its core phase.
REMODEL-1 followed a similar Phase III design. Earlier Novartis trial documentation listed an enrollment target of approximately 800 patients for that study as well.
Together, the studies provide a substantial late-stage dataset for evaluating remibrutinib in relapsing MS.
Safety Profile Strengthens Remibrutinib Case
Safety is particularly important for BTK inhibitors because liver toxicity has complicated development of some medicines in the class.
Novartis reported that remibrutinib maintained a favorable safety profile in REMODEL-1 and REMODEL-2. No liver-safety signal was identified, and there were no cases meeting Hy’s Law criteria, a commonly used indicator of potentially serious drug-induced liver injury.
The safety findings were also consistent with the wider remibrutinib development programme, which includes more than 4,500 clinical-trial participants across several indications.
Reuters reported that two deaths occurred during the REMODEL studies but were considered unrelated to treatment. More complete safety information will be needed when Novartis presents the full trial dataset.
Remibrutinib Already Has Broader Development History
Remibrutinib is not a new molecule entering clinical development for the first time.
The therapy is already approved in several markets for chronic spontaneous urticaria under the Rhapsido brand and has been investigated across additional immune-mediated diseases.
In February 2026, Novartis also reported positive Phase III results in chronic inducible urticaria, where remibrutinib met the primary endpoint across three common disease subtypes.
This broader clinical experience provides Novartis with a substantial safety and manufacturing foundation as it pursues the much larger multiple sclerosis market.
Novartis Plans Global Regulatory Submissions
The company plans to submit remibrutinib for regulatory approval in relapsing multiple sclerosis to health authorities worldwide following the positive REMODEL results.
Full data will be particularly important for regulators, clinicians and investors when comparing the therapy with established MS treatments and other BTK inhibitors currently in development.
Key questions will include the exact magnitude of relapse reduction, MRI benefits, disability effects, treatment discontinuations and longer-term safety.
Remibrutinib MS Treatment Enters Critical Stage
The positive REMODEL-1 and REMODEL-2 findings represent an important milestone for Novartis and for the broader development of BTK inhibitors in multiple sclerosis.
Remibrutinib demonstrated superiority over teriflunomide for relapse reduction, improved key MRI outcomes and produced encouraging disability-progression results while avoiding a reported liver-safety signal.
The results remain topline findings, meaning the complete dataset must still undergo detailed scientific evaluation.
If the full results confirm the early announcement, the remibrutinib MS treatment could provide patients with another oral option combining strong inflammatory disease control with a potentially differentiated safety profile.
Novartis’ upcoming presentation and global regulatory submissions will determine whether those Phase III results can translate into a new treatment choice for people living with relapsing multiple sclerosis.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
